New wearable injector tested for common psoriasis drug
NCT ID NCT06937619
Summary
This study tested how the body absorbs the drug risankizumab when delivered using a new, wearable on-body injector. It involved 263 healthy adult volunteers. The main goal was to measure drug levels in the blood and check for safety, not to treat any disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 271954
Grayslake, Illinois, 60030, United States
-
CenExel ACT- Anaheim Clinical Trials /ID# 274805
Anaheim, California, 92801, United States
-
Collaborative Neuroscience Research CNS /ID# 275212
Los Alamitos, California, 90720, United States
-
Cpmi /Id# 274464
Miami, Florida, 33172, United States
Conditions
Explore the condition pages connected to this study.